Xiang Anbo, Kanematsu Masahiro, Mitamura Mana, Kikkawa Hideo, Asano Satoshi, Kinoshita Mine
Pharmacology Department, Tsukuba Research Laboratories, GlaxoSmithKline K.K., 43 Wadai, Tsukuba, Ibaraki 300-4247, Japan.
Invest Radiol. 2006 Sep;41(9):704-12. doi: 10.1097/01.rli.0000236921.77810.56.
The purposes of this study were to develop an osteoporosis model in a short period of 2 weeks after ovariectomy in mice and to investigate whether analysis of microcomputed tomography (muCT) 3-dimensional bone parameters could provide useful information on the mechanism of action of antiosteoporotic agents.
Mice were ovariectomized (OVX) or sham-operated, and the OVX mice were treated daily with 17beta-estradiol (E2), parathyroid hormone (PTH[1-34]), raloxifene, rolipram, or vehicle for 2 weeks. On day 14 post-OVX, the left femur bones were removed and then the distal metaphyseal bone was analyzed by both muCT and histomorphometry.
The trabecular bone volume, thickness, number, and connectivity significantly decreased and the number of osteoclasts increased in OVX mice. Treatment of OVX animals with each of the 4 antiosteoporotic agents significantly increased the bone volume and improved the bone architecture. However, the improvement of trabecular thickness in the rolipram-treated group and that of cortical thickness in the PTH(1-34)-treated group were the most marked, whereas the improvement of connectivity in the rolipram-treated group was the least among the drug-treated groups. These different improving effects of agents on the bone parameters reflect the differential effects of these agents on bone formation and bone resorption.
This study demonstrated the feasibility of evaluating the effect of the antiosteoporotic agents within 2 weeks after ovariectomy in mice. The muCT analysis may serve as a valuable tool, specifically in a high-throughput pharmacological screening test, offering useful information regarding the effects of test compounds on both bone resorption and formation.
本研究的目的是在小鼠卵巢切除术后2周的短时间内建立骨质疏松模型,并研究微计算机断层扫描(μCT)三维骨参数分析是否能为抗骨质疏松药物的作用机制提供有用信息。
将小鼠进行卵巢切除(OVX)或假手术,对OVX小鼠每天给予17β-雌二醇(E2)、甲状旁腺激素(PTH[1-34])、雷洛昔芬、咯利普兰或赋形剂,持续2周。在OVX后第14天,取出左股骨,然后通过μCT和组织形态计量学分析远端干骺端骨。
OVX小鼠的小梁骨体积、厚度、数量和连通性显著降低,破骨细胞数量增加。用4种抗骨质疏松药物中的每一种治疗OVX动物均显著增加了骨体积并改善了骨结构。然而,咯利普兰治疗组小梁厚度的改善和PTH(1-34)治疗组皮质厚度的改善最为明显,而咯利普兰治疗组连通性的改善在药物治疗组中是最小的。这些药物对骨参数的不同改善作用反映了它们对骨形成和骨吸收的不同作用。
本研究证明了在小鼠卵巢切除术后2周内评估抗骨质疏松药物效果的可行性。μCT分析可作为一种有价值的工具,特别是在高通量药理学筛选试验中,提供有关受试化合物对骨吸收和形成影响的有用信息。